Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology Coding Corner Question: Sacroiliac Injection with Office Visit

From the College  |  Issue: July 2015  |  July 13, 2015

Coding for SI Injections with Office Visit

A female patient previously diagnosed with sacroiliitis and ankylosing spondylitis returns to the office for a follow-up visit. The patient reports her lower back has been stiff and swollen for the past couple of weeks. She is currently on celecoxib and ranitidine, and mentions that she had some nausea after taking the celecoxib. She works full time and is a nonsmoker.

On examination, the patient is alert and oriented. She has normal vital signs. She is 5’7″ and weighs 140 lbs., and her temperature 98º. Her head, eyes, ears, nose and throat exam is normal. There is no lymphadenopathy. Her lungs are clear. Her heart is at a regular rate and rhythm, with no murmurs or friction rubs, and there are good peripheral pulses. Her abdomen is soft, non-tender, with no mass or hepatosplenomegaly. The patient’s physical examination is remarkable for a large effusion of the sacroiliac joint. The physician makes the decision to give the patient an injection via CT guidance. The physician explains therapeutic options to the patient, including risks and benefits, and performs the SI injection with 10 mg of triamcinolone acetonide to the lower back region. The patient is taken off of celecoxib. A new prescription for the pain is prescribed and the patient is given discharge instructions on post–sacroiliac injection care and follow-up.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

How is this encounter coded?

Share: 

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:BillingCodingoffice visitpatient carerheumatologistsacroiliac injection

Related Articles

    Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis

    May 1, 2014

    New research clarifies terminology used for diagnosis, but questions remain around epidemiology, genetics and management of patients with axial skeletal inflammation

    Biophoto Associates / Science Source

    A Stiff Man: A Case Study in Ankylosing Spondylitis

    July 12, 2017

    First Appearances I watched the old man, his back painfully bent, shuffle toward the scale. A blocky rigidity draped over him. His feet seemed stuck to the floor. His head hung heavily over his chest. Observing him from the end of the hallway, instead of a face, I saw only a mound of shaggy, matted…

    Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

    December 13, 2016

    Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…

    Celecoxib & Cardiovascular Death: NSAID Safety Under Review

    December 7, 2016

    A recent study showed that at moderate doses celecoxib may be noninferior with respect to cardiovascular safety compared with ibuprofen or naproxen…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences